Todd A Florin1, Lilliam Ambroggio2, Cole Brokamp3,4, Yin Zhang3,4, Mantosh Rattan5,6, Eric Crotty5,6, Michael A Belsky7, Sara Krueger6, Thomas N Epperson8, Andrea Kachelmeyer4,9, Richard Ruddy4,9, Samir S Shah4,10. 1. Department of Pediatrics, Feinberg School of Medicine, Northwestern University and Division of Emergency Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; taflorin@luriechildrens.org. 2. Department of Pediatrics, University of Colorado and Sections of Emergency Medicine and Hospital Medicine, Children's Hospital Colorado, Aurora, Colorado. 3. Divisions of Biostatistics and Epidemiology. 4. Department of Pediatrics. 5. Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 6. College of Medicine, University of Cincinnati, Cincinnati, Ohio. 7. School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; and. 8. School of Medicine, University of Louisville, Louisville, Kentucky. 9. Emergency Medicine, and. 10. Hospital Medicine and Infectious Diseases and.
Abstract
BACKGROUND: Host biomarkers predict disease severity in adults with community-acquired pneumonia (CAP). We evaluated the association of the white blood cell (WBC) count, absolute neutrophil count (ANC), C-reactive protein (CRP), and procalcitonin with the development of severe outcomes in children with CAP. METHODS: We performed a prospective cohort study of children 3 months to 18 years of age with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (eg, hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (eg, intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP. RESULTS: Of 477 children, there were no statistical differences in the median WBC count, ANC, CRP, or procalcitonin across severity categories. No biomarker had adequate discriminatory ability between severe and nonsevere disease (area under the curve [AUC]: 0.53-0.6 for suspected CAP and 0.59-0.64 for radiographic CAP). In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12; 95% confidence interval, 1.0-1.25). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low. CONCLUSIONS: WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate nonsevere from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes.
BACKGROUND: Host biomarkers predict disease severity in adults with community-acquired pneumonia (CAP). We evaluated the association of the white blood cell (WBC) count, absolute neutrophil count (ANC), C-reactive protein (CRP), and procalcitonin with the development of severe outcomes in children with CAP. METHODS: We performed a prospective cohort study of children 3 months to 18 years of age with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (eg, hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (eg, intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP. RESULTS: Of 477 children, there were no statistical differences in the median WBC count, ANC, CRP, or procalcitonin across severity categories. No biomarker had adequate discriminatory ability between severe and nonsevere disease (area under the curve [AUC]: 0.53-0.6 for suspected CAP and 0.59-0.64 for radiographic CAP). In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12; 95% confidence interval, 1.0-1.25). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low. CONCLUSIONS: WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate nonsevere from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes.
Authors: Salvador Bello; Ana B Lasierra; Elisa Mincholé; Sergio Fandos; Maria Angeles Ruiz; Elisabeth Vera; Francisco de Pablo; Miguel Ferrer; Rosario Menendez; Antoni Torres Journal: Eur Respir J Date: 2011-11-10 Impact factor: 16.671
Authors: A Lacoma; N Rodríguez; C Prat; J Ruiz-Manzano; F Andreo; A Ramírez; A Bas; M Pérez; V Ausina; J Domínguez Journal: Eur J Clin Microbiol Infect Dis Date: 2011-08-26 Impact factor: 3.267
Authors: S Krüger; S Ewig; R Marre; J Papassotiriou; K Richter; H von Baum; N Suttorp; T Welte Journal: Eur Respir J Date: 2007-10-24 Impact factor: 16.671
Authors: David T Huang; Lisa A Weissfeld; John A Kellum; Donald M Yealy; Lan Kong; Michael Martino; Derek C Angus Journal: Ann Emerg Med Date: 2008-03-17 Impact factor: 5.721
Authors: Stefan Krüger; Santiago Ewig; Jana Papassotiriou; Jan Kunde; Reinhard Marre; Heike von Baum; Norbert Suttor; Tobias Welte Journal: Respir Res Date: 2009-07-12
Authors: Chris Stockmann; Krow Ampofo; Jarrett Killpack; Derek J Williams; Kathryn M Edwards; Carlos G Grijalva; Sandra R Arnold; Jonathan A McCullers; Evan J Anderson; Richard G Wunderink; Wesley H Self; Anna Bramley; Seema Jain; Andrew T Pavia; Anne J Blaschke Journal: J Pediatric Infect Dis Soc Date: 2018-02-19 Impact factor: 3.164
Authors: Todd A Florin; Lilliam Ambroggio; Samir S Shah; Richard M Ruddy; Eric S Nylen; Lauren Balmert Journal: Pediatr Infect Dis J Date: 2021-12-01 Impact factor: 2.129
Authors: Laura F Sartori; Yuwei Zhu; Carlos G Grijalva; Krow Ampofo; Per Gesteland; Jakobi Johnson; Rendie McHenry; Donald H Arnold; Andrew T Pavia; Kathryn M Edwards; Derek J Williams Journal: Hosp Pediatr Date: 2021-02-12
Authors: Julia A Bielicki; Wolfgang Stöhr; Sam Barratt; David Dunn; Nishdha Naufal; Damian Roland; Kate Sturgeon; Adam Finn; Juan Pablo Rodriguez-Ruiz; Surbhi Malhotra-Kumar; Colin Powell; Saul N Faust; Anastasia E Alcock; Dani Hall; Gisela Robinson; Daniel B Hawcutt; Mark D Lyttle; Diana M Gibb; Mike Sharland Journal: JAMA Date: 2021-11-02 Impact factor: 56.272
Authors: Sunil Kumar Kasundriya; Mamta Dhaneria; Aditya Mathur; Ashish Pathak Journal: Int J Environ Res Public Health Date: 2020-06-27 Impact factor: 3.390
Authors: Todd Adam Florin; Daniel Joseph Tancredi; Lilliam Ambroggio; Franz E Babl; Stuart R Dalziel; Michelle Eckerle; Santiago Mintegi; Mark Neuman; Amy C Plint; Nathan Kuppermann Journal: BMJ Open Date: 2020-12-02 Impact factor: 2.692
Authors: Todd A Florin; Lilliam Ambroggio; Cole Brokamp; Yin Zhang; Eric S Nylen; Mantosh Rattan; Eric Crotty; Michael A Belsky; Sara Krueger; Thomas N Epperson; Andrea Kachelmeyer; Richard M Ruddy; Samir S Shah Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079